On p. 34 of the latest, post-results presentation, the company now lists a "NASH Centric Transaction" as a value driver in 2018 (separately from the Pediatric NAFLD Phase 2 topline results in 4Q/2018 and ASH Phase 2 results in 1Q/2019).
"NASH Centric Transaction." Sure sounds like partnership talk to me.
Company also expects results from colitis pre-clinical studies and US Army and US Navy Travelan trial results in 2018.
http://www.immuron.com/assets/Uploads/Immuron-Corporate-Presentation-March-2018-V4.pdf
Add to My Watchlist
What is My Watchlist?
